A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Trial Profile

A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Pazopanib (Primary) ; Vorinostat (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 27 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 07 Jun 2016 Results of a retrospective analysis of pazopanib from 4 phase I trials in patients with advanced sarcoma (NCT01339871, NCT01430572, NCT01454804, NCT01454804) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top